Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Effectiveness and Safety of Traditional Chinese Medicine in Treatment of Primary Sjögren’s Syndrome Patients: A Meta-analysis

Author(s): Hui Liu, Xiaoxin Wang, Weiran Liu, Guannan He, Xiaodong Liang* and Yuejuan Bian*

Volume 26, Issue 14, 2023

Published on: 28 April, 2023

Page: [2554 - 2571] Pages: 18

DOI: 10.2174/1386207326666230322092252

Price: $65

Abstract

Background: Primary Sjögren’s Syndrome (pSS) is an autoimmune disease. It can damage the salivary and lacrimal glands and is characterized by dry mouth and eye symptoms, which seriously affects people’s normal life. Both modern medicine and Traditional Chinese medicine (TCM) have certain effects in treating SS. However, there are different theories about which treatment is more appropriate.

Objective: The aim of this research was to compare the efficacy and safety of TCM to Western Medicine in the treatment of pSS.

Methods: We collected randomized controlled trials (RCTs) of TCM, integrating traditional Chinese and Western medicine for the treatment of pSS in Chinese and foreign databases.

Results: A total of 13 articles were eventually included with 780 cases. The final results were expressed in odds ratio (OR), mean difference (MD), 95% confidence interval (CI), and overall effect (z). The effective rate was 86.03% in the TCM group and 67.75% in the western medicine group. Results of the effective rate were OR = 3.57; 95% CI = 2.44-5.23; z = 6.56; p＜0.00001, ESR were MD = -6.90; 95% CI = -10.76--3.05; z = 3.51; p = 0.0005＜0.05, Schirmer’s test were MD = 3.39; 95% CI = 1.92-4.86; z = 4.5; p＜0.00001, salivary flow were MD = 0.62; 95% CI = 0.16-1.07; z = 2.63; p = 0.009＜0.05, and adverse reactions were OR = 0.35; 95% CI = 0.17-0.72; z = 2.84; p = 0.004.

Conclusion: TCM has a remarkable effect on the treatment of pSS. Among them Yiguanjian decoction and Liuwei Dihuang decoction were effective prescriptions with the highest frequency of application. Rehmanniae Radix (Rehmannia glutinosa Libosch.) and Ophiopogonis Radix (Ophiopogon japonicus (L. f.) Ker-Gawl.) were the most frequently used TCM.

« Previous Next »
[1]
Cao, Y.J.; Duan, F. Professor Guo Huiqing has an experience in the treatment of Sjögren’s syndrome. TCM Res., 2012, 25(11), 58-60.
[2]
Huang, T.; Zhang, H.D.; Wang, Z.X.; Wang, Z.S.; Jing, L. Progress of Sjögren’s syndrome. Rheum. Arthritis, 2012, 1(04), 69-71.
[3]
Gottenberg, J.E. Primary Sjögren’s syndrome: Pathophysiological, clinical and therapeutic advances. Joint Bone Spine, 2009, 76(6), 591-594.
[http://dx.doi.org/10.1016/j.jbspin.2009.09.006] [PMID: 19932634]
[4]
Liu, J.; Hu, J.D.; Xue, L. Application of “Red Dragon Stir the Sea” in Sjögren’s syndrome. Henan Trad. Chinese Med., 2012, 32(11), 1429-1430.
[5]
Shahane, A.; Patel, R. The epidemiology of Sjögren’s syndrome. Clin. Epidemiol., 2014, 6, 247-255.
[http://dx.doi.org/10.2147/CLEP.S47399] [PMID: 25114590]
[6]
Feng, L.; Xu, Y.Y.; Li, M.Y. Efficacy of hydroxychloroquine sulfate for the treatment of Sjögren’s syndrome and its effect on serum IL-17 ESR CRP IgG levels in patients. Hebei Med., 2021, 27(2), 334-339.
[7]
Luo, D.; Chen, Y.; Zhou, N.; Li, T.; Wang, H. Blockade of Th17 response by IL-38 in primary Sjögren’s syndrome. Mol. Immunol., 2020, 127, 107-111.
[http://dx.doi.org/10.1016/j.molimm.2020.09.006] [PMID: 32950755]
[8]
Zhang, W.; Li, X.M.; Xu, D.; Liu, D.Z.; Xu, J. Practice for diagnosis and treatment of primary Sjögren’s syndrome. Chin. J. Integr. Med., 2020, 04, 269-270.
[9]
Vivino, F.B.; Bunya, V.Y.; Massaro-Giordano, G.; Johr, C.R.; Giattino, S.L.; Schorpion, A.; Shafer, B.; Peck, A.; Sivils, K.; Rasmussen, A.; Chiorini, J.A.; He, J.; Ambrus, J.L., Jr Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin. Immunol., 2019, 203, 81-121.
[http://dx.doi.org/10.1016/j.clim.2019.04.009] [PMID: 31022578]
[10]
Qin, B.; Wang, J.; Yang, Z.; Yang, M.; Ma, N.; Huang, F.; Zhong, R. Epidemiology of primary Sjögren’s syndrome: A systematic review and meta-analysis. Ann. Rheum. Dis., 2015, 74(11), 1983-1989.
[http://dx.doi.org/10.1136/annrheumdis-2014-205375] [PMID: 24938285]
[11]
Zhang, Y.H. One case of Sjögren’s syndrome was treated in traditional Chinese medicine. China Nurs. Med., 2016, 25(10), 1114-1116.
[12]
Yu, X.X.; Xia, F. Pathogenesis of Sjögren’s syndrome and its traditional Chinese medicine treatment. Fujian Trad. Chinese Med., 2015, 46(02), 61-63.
[13]
Bombardieri, M.; Baldini, C.; Alevizos, I.; Akpek, E.; Baer, A.N. Highlights of the 14th International symposium in Sjögren’s syndrome. Clin. Exp. Rheumatol., 2018, 36(3)(Suppl. 112), 3-13.
[PMID: 30156541]
[14]
Fasano, S.; Mauro, D.; Macaluso, F.; Xiao, F.; Zhao, Y.; Lu, L.; Guggino, G.; Ciccia, F. Pathogenesis of primary Sjögren’s syndrome beyond B lymphocytes. Clin. Exp. Rheumatol., 2020, 38(Suppl. 126), 315-323.
[PMID: 33095148]
[15]
Xue, B.Y.; Li, X.R.; Huang, H. Huang Huang jingfang internal medical case (10)-Sjögren’s syndrome test case 2. Shanghai J. Trad. Chinese Med., 2012, 46(10), 17-19.
[16]
Chen, X.; Wu, H.; Wei, W. Advances in the diagnosis and treatment of Sjogren’s syndrome. Clin. Rheumatol., 2018, 37(7), 1743-1749.
[http://dx.doi.org/10.1007/s10067-018-4153-8] [PMID: 29804149]
[17]
Srivastava, A.; Makarenkova, H.P. Innate immunity and biological therapies for the treatment of Sjögren’s syndrome. Int. J. Mol. Sci., 2020, 21(23), 9172.
[http://dx.doi.org/10.3390/ijms21239172] [PMID: 33271951]
[18]
Odani, T.; Chiorini, J.A. Targeting primary Sjögren’s syndrome. Mod. Rheumatol., 2019, 29(1), 70-86.
[http://dx.doi.org/10.1080/14397595.2018.1546268] [PMID: 30424703]
[19]
Sada, P.R.; Isenberg, D.; Ciurtin, C. Biologic treatment in Sjogren’s syndrome. Rheumatology, 2015, 54(2), 219-230.
[http://dx.doi.org/10.1093/rheumatology/keu417] [PMID: 25342375]
[20]
Niu, G.H.; Zhang, Y.F.; Gao, Y.J.; Yan, F. Peripheral blood T cell subsets and the expression of IL-17 and IL-10 in primary Sjögren’s syndrome. Jianyan Yixue Yu Linchuang, 2015, 12(18), 2664-2665.
[21]
Zhou, J.; Chen, X.J.; Mao, J.C.; Gu, J.H. Clinical study on the treatment of primary Sjögren’s syndrome. Chinese Med. TCM Sci. Technol., 2020, 27(5), 682-684.
[22]
Hou, J.Q.; Xue, L. Overview of the pathogenesis of primary Sjögren’s syndrome. Modern Immunol., 2019, 39(1), 58-63.
[23]
Kampa, M.; Notas, G.; Stathopoulos, E.N.; Tsapis, A.; Castanas, E. The TNFSF members APRIL and BAFF and their receptors TACI, BCMA, and BAFFR in oncology, with a special focus in breast cancer. Front. Oncol., 2020, 10, 827.
[http://dx.doi.org/10.3389/fonc.2020.00827] [PMID: 32612943]
[24]
Nocturne, G.; Mariette, X. B cells in the pathogenesis of primary Sjögren syndrome. Nat. Rev. Rheumatol., 2018, 14(3), 133-145.
[http://dx.doi.org/10.1038/nrrheum.2018.1] [PMID: 29416129]
[25]
Shi, Y.H.; Liu, Y.; Wei, N.; Liu, X.P.; Zhu, Y.L. Study on the intervention effect of blood circulation and detoxification prescription on interferon-γ, B cell activation factor and its receptors in Sjögren’s syndrome mice. Global Trad. Chinese Med., 2016, 9(1), 14-20.
[26]
Wang, G.; Qi, W.X.; Yan, Y.F.; Wang, T.; Zou, F.X.; Jiang, G.G.; Li, Z.T. Progress in the mechanism of TCM Treatment of Sjögren’s syndrome. Chinese J. Exper. Formulol., 2021, 27(20), 227-235.
[27]
Li, Y.M.; Xue, L. The role of AQP5 in the pathogenesis of Sjögren’s syndrome. China J. Trad. Chinese Med., 2019, 37(10), 2369-2372.
[28]
Liu, D.; Qin, Y.; Xie, Z.M.; Liu, D.Y.; Wang, J.; Zhu, Q.S.; Wang, X.C. Effects of serum containing qi and Yin and prescription on the expression of AQP5 and M3R in dry integrated human submandibular gland cells. Chinese J. Integr. Trad. Chinese West. Med., 2019, 39(3), 330-334.
[29]
Norheim, K.B.; Jonsson, G.; Harboe, E.; Hanasand, M.; Gøransson, L.; Omdal, R. Oxidative stress, as measured by protein oxidation, is increased in primary Sjøgren’s syndrome. Free Radic. Res., 2012, 46(2), 141-146.
[http://dx.doi.org/10.3109/10715762.2011.645206] [PMID: 22126431]
[30]
Charras, A.; Arvaniti, P.; Le Dantec, C.; Dalekos, G.N.; Zachou, K.; Bordron, A.; Renaudineau, Y. JAK inhibitors and oxidative stress control. Front. Immunol., 2019, 10, 2814.
[http://dx.doi.org/10.3389/fimmu.2019.02814] [PMID: 31867003]
[31]
Wang, G.Z.; Liu, J.; Fan, H.X.; Huang, C.B.; Wang, Y.; Chen, R.L.; Wan, L. Exploring the effect of Xinfeng capsule on cardiac function in Sjögren’s syndrome patients based on oxidative stress. Shi Zhen Nat. Chinese Med., 2015, 26(7), 1672-1674.
[32]
Ryo, K.; Yamada, H.; Nakagawa, Y.; Tai, Y.; Obara, K.; Inoue, H.; Mishima, K.; Saito, I. Possible involvement of oxidative stress in salivary gland of patients with Sjogren’s syndrome. Pathobiology, 2006, 73(5), 252-260.
[http://dx.doi.org/10.1159/000098211] [PMID: 17314496]
[33]
Sha, M.H. Macon polysaccharide mechanism based on the TLR4/MyD88/NF-κB signaling pathway regulating the submandibular inflammatory microenvironment of Sjögren’s syndrome; Nanjing University of Traditional Chinese Medicine, 2019.
[34]
Zhu, H.H.; Wang, Y.; Lu, Y. Study on the treatment of Sjögren’s internal fever syndrome from lung, spleen, liver and kidney. Jiangsu Trad. Chinese Med., 2015, 47(11), 41-43.
[35]
Yao, Z.F.; Cui, J.; Yang, J.Z. Observation of the clinical efficacy of 20 cases of Sjögren’s syndrome in ZYT. Chinese Folk Therapy, 2016, 24(3), 52-53.
[36]
Wu, Z.H. Clinical observation of the treatment of primary Sjögren’s syndrome. Hubei J. Trad. Chinese Med., 2013, 35(10), 46-47.
[37]
Wang, W.R.; Ren, Z.X.; Chen, L.; Liu, S.; Shi, L.C. Yan Xiaoping’s experience in treating Sjögren’s syndrome from the kidney theory. Chinese J. Trad. Chinese Med., 2021, 36(4), 2108-2111.
[38]
Lin, C.Z.; Huang, S.X.; Qin, Y.; Sun, H.; Li, Z.Y.; Wang, X.C. Effect of supplementing qi, nourishing Yin and removing blood stasis on TLR-IFN-BAFF signaling in the submandibular glands of Sjögren’s syndrome NOD mice. Chinese J. Integ. Trad. Chinese West. Med., 2017, 37(12), 1487-1490.
[39]
Ma, W.K.; Zeng, P.; He, X.L.; Ning, Q.Y.; Zhou, J.; Hou, L. Effect of Runzao soup on submandibular glands in Sjögren’s syndrome model. China J. Trad. Chinese Med., 2017, 35(11), 2912-2914.
[40]
Ma, W.J.; Jiang, Y.; Fang, Y.F. Clinical study on 23 cases of dry syndrome. Sichuan Trad. Chinese Med., 2014, 32(03), 88-91.
[41]
Meng, Q.Y.; Xiao, R.C.; Li, D.S. Observation of the curative effect in the treatment of primary Sjögren’s syndrome. Guangming Trad. Chinese Med., 2017, 32(10), 1424-1426.
[42]
Tong, Y.; Zhang, W.P.; Shao, Z.L.; Yang, J.C. Clinical effect of nourishing Yin and thinning liver method in treating primary Sjögren’s syndrome with Yin deficiency and liver depression. World’s Latest Med. Inform. Abstract, 2019, 19(96), 268.
[43]
Li, J.; Xiao, J. Effect of addition and decrease on salivary gland and lacrimal gland secretion function and ESR, CRP and IgG in patients with primary Sjögren’s syndrome. J. Modern Integr. Trad. Chinese West. Med., 2016, 29(18), 2016-2019.
[44]
Mo, X.Y. Clinical study on the treatment of Primary Sjögren’s syndrome. Shandong J. Trad. Chinese Med., 2015, 34(06), 418-420.
[45]
Ma, R. Effect of consistent decoction and hydroxychloroquine sulfate on clinical efficacy and serum Th17/Treg ratio changes in patients with liver and kidney Yin deficiency in Sjögren’s syndrome. Liaoning Zhongyiyao Daxue Xuebao, 2020, 22(03), 116-119.
[46]
Zhuo, C.Q.; Zhou, W.G.; Wu, W.S.; Jiang, Q.Y.; Hu, Y.X. Observation on the curative effect of Rehmannia chinensis soup combined with traditional Chinese medicine in the treatment of Sjögren’s syndrome. Shanxi Trad. Chinese Med., 2018, 34(09), 13-15.
[47]
Ye, Y.P.; Zheng, S.M. Clinical observation of 62 cases of Sjögren’s syndrome. Zhejiang J. Integr. Trad. Chinese West. Med., 2012, 22(10), 801-802.
[48]
Yao, Z. Clinical observation of 32 cases of primary Sjögren’s syndrome. Jiangxi Trad. Chinese Med., 2017, 48(11), 46-48.
[49]
An, Q.; Ding, J.Y.; Liu, L.J.; Lv, T.T.; Ma, F.Y.; Yu, Y. Treatment of primary Sjögren syndrome in 36 cases by nourishing liver and spleen method. Shaanxi Trad. Chinese Med., 2015, 36(01), 29-31.
[50]
Yang, SF.; Liu, YZ.; Liu, XY. Observation of curative effect in Sjögren’s syndrome. Commun. Phys. China, 2017, 33(18), 94-95.
[51]
Shen, H.B. Clinical observation of rehydration soup for Sjögren’s syndrome. Chin. Med. J., 2013, 48(07), 94-96.
[52]
Lu, X.Y.; Yu, H.M.; Yin, F.X.; Lin, J.; Fang, W.L.; Sun, Y.; Wang, J.T.; Wang, Z.Y. Clinical observation of complementary and supplementation in the treatment of Sjögren’s syndrome. J. Harbin Med. Univ., 2020, 54(02), 148-151.
[53]
Wei, S.F.; Liang, L.N.; Li, X.L.; Xu, L. Clinical observation of 20 patients of Sjögren’s syndrome. Trad. Chinese Med. Guide, 2012, 18(05), 57-58.
[54]
Ministry of Health of the PRC. Guiding Principles for Clinical Research of New Chinese Medicine; People's Health Publishing House: Beijing, 1995.
[55]
Zhu, C.; Jiang, T.; Cao, H.; Sun, W.; Chen, Z.; Liu, J. Longitudinal analysis of meta-analysis literatures in the database of ISI Web of Science. Int. J. Clin. Exp. Med., 2015, 8(3), 3559-3565.
[PMID: 26064249]
[56]
Zajac, A.E.; Adams, A.S.; Turner, J.H. A systematic review and meta-analysis of probiotics for the treatment of allergic rhinitis. Int. Forum Allergy Rhinol., 2015, 5(6), 524-532.
[http://dx.doi.org/10.1002/alr.21492] [PMID: 25899251]
[57]
Yargawa, J.; Leonardi-Bee, J. Male involvement and maternal health outcomes: Systematic review and meta-analysis. J. Epidemiol. Community Health, 2015, 69(6), 604-612.
[http://dx.doi.org/10.1136/jech-2014-204784] [PMID: 25700533]
[58]
Zhao, Y.L.; Li, H.; Fu, S.F.; Guo, J.C. Study on data mining of clinical drug use rule of Sjögren’s Syndrome in the past 20 years. Rheumat. Arthritis, 2020, 9(11), 14-18.
[59]
Feng, L.; Ma, L. Observation of the clinical efficacy of paeoniae baseagin in the treatment of primary Sjögren’s syndrome. West China Med., 2013, 28(09), 1423-1425.
[60]
Gan, M.Z.; Yu, J.J.; Deng, Y. Clinical effect of triptoldoside and paeoniflorin syndrome and its effect on serum ACL and RF. China J. Trad. Chinese Med., 2022, 40(2), 94-96.
[61]
Guo, Y.; Ji, W.; Lu, Y.; Wang, Y. Triptolide reduces salivary gland damage in a non-obese diabetic mice model of Sjögren’s syndrome via JAK/STAT and NF-κB signaling pathways. J. Clin. Biochem. Nutr., 2021, 68(2), 131-138.
[http://dx.doi.org/10.3164/jcbn.20-15] [PMID: 33879964]
[62]
Wang, J.; Wang, F. Research progress of treatment of total side in autoimmune diseases. Med. Rev., 2021, 27(22), 4481-4485.
[63]
Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.; Fox, P.C.; Fox, R.I.; Kassan, S.S.; Pillemer, S.R.; Talal, N.; Weisman, M.H. european study group on classification criteria for sjögren’s syndrome. Classification criteria for Sjogren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis., 2002, 61(6), 554-558.
[http://dx.doi.org/10.1136/ard.61.6.554] [PMID: 12006334]
[64]
Seror, R.; Mariette, X.; Bowman, S.; Baron, G.; Gottenberg, J.E.; Boostma, H.; Theander, E.; Tzioufas, A.; Vitali, C.; Ravaud, P. European league against rheumatism sjögren’s task force. Accurate detection of changes in disease activity in primary Sjögren’s syndrome by the European league against rheumatism sjögren’s syndrome disease activity index. Arthritis Care Res. (Hoboken), 2010, 62(4), 551-558.
[http://dx.doi.org/10.1002/acr.20173] [PMID: 20391511]
[65]
Seror, R.; Ravaud, P.; Bowman, S.J.; Baron, G.; Tzioufas, A.; Theander, E.; Gottenberg, J.E.; Bootsma, H.; Mariette, X.; Vitali, C. EULAR Sjögren’s Task Force. EULAR Sjögren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann. Rheum. Dis., 2010, 69(6), 1103-1109.
[http://dx.doi.org/10.1136/ard.2009.110619] [PMID: 19561361]
[66]
The rheumatology branch of the chinese medical association. guidelines for the diagnosis and treatment of sjögren’s syndrome (draft). Chinese J. Rheumat., 2003, (7), 446-448.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy